Mestag Therapeutics founding investigator Prof. David A. Tuveson elected to US National Academy of Medicine

October 20, 2022

Cambridge, UK, October 20, 2022 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, is pleased to congratulate Prof. David A. Tuveson, one of its founding investigators, on his election to the US National Academy of Medicine.

Election to the Academy is considered one of the highest honours in the fields of health and medicine and recognises individuals who have demonstrated outstanding professional achievement and commitment to service.

David A. Tuveson, MD, PhD, FAACR, is Roy J. Zuckerberg Professor and Director, Cold Spring Harbor Laboratory Cancer Center. Prof Tuveson was nominated for his transformative leadership in pancreatic cancer biology. His work has led to the development of powerful pancreatic cancer models, which has been fundamental to preclinical studies of understanding targeted therapy and treatment of pancreatic cancer.

At Cold Spring Harbor Laboratory, his lab co-developed pancreatic organoid cancer models with Prof. Dr Hans Clevers, and made a series of observations regarding cancer fibroblasts, redox regulation, and pancreatitis. His awards include the Rita Allen Scholarship and the Jan Waldenström Award, and the Hamdan Award.

Susan Hill, PhD, Chief Executive Officer of Mestag Therapeutics, said: “Many congratulations to David on this important and well-deserved recognition of his outstanding contributions to pancreatic cancer and fibroblast biology. We are honoured to work with David as a key founding investigator of our company.”

For enquiries, please contact:

Jonathan Birt
M: +44 (0)7860 361746

About Mestag Therapeutics

Mestag’s mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Our founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham and Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. Mestag is progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology.

Mestag is supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is headquartered in Cambridge, UK. In 2021, Mestag was recognised on the Fierce 15 list of innovative biotechnology companies.

Back to News